<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53474">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01683331</url>
  </required_header>
  <id_info>
    <org_study_id>1R01DK092475-01</org_study_id>
    <nct_id>NCT01683331</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Prevent New Onset Diabetes After Transplantation</brief_title>
  <acronym>ITP-NODAT</acronym>
  <official_title>A Clinical Trial to Prevent New Onset Diabetes After Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Specific Aim 1: To determine the clinical efficacy of early initiation of insulin therapy in
      decreasing the incidence of NODAT among de novo kidney transplant patients with manifested
      post-transplant hyperglycemia during the first week after transplantation.

      Hypothesis 1: Early initiation of insulin therapy protects beta-cell from early stress
      related to the surgery and use of higher doses of immunosuppressive medications, and leads
      to lower incidence of NODAT at 1 and 2 years.

      Specific Aim 2: To determine the improvement in overall glycemic control with the early
      initiation of insulin therapy.

      Hypothesis 2: Early initiation of insulin therapy results in greater overall control of
      glycemia compared to standard care of dietary counseling, life-style modification, oral
      hypoglycemic agents and/or insulin as needed at 1 year.

      Specific Aim 3: To determine the improvement in beta-cell function among patients assigned
      to the early initiation of insulin therapy at one year post-transplantation.

      Hypothesis 3: Early initiation of insulin therapy protects beta-cell from glucotoxicity of
      post-transplant hyperglycemia and preserves better beta-cell function at 1 year.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>The incidence of NODAT 12 months after kidney transplantation</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>NODAT will be defined according to American Diabetes Association definition:
Fasting glucose level equal or greater than 126 mg/dl on two separate blood testings; and/or
2 hours OGTT values equal or greater than 200 mg/dl; and/or
Glycosylated hemoglobin A1c equal or greater than 6.5; and/or
On oral hypoglycemic agents and/or insulin therapy;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of NODAT 24 months after kidney transplantation</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>NODAT will be defined according to American Diabetes Association definition:
Fasting glucose level equal or greater than 126 mg/dl on two separate blood testings; and/or
2 hours OGTT values equal or greater than 200 mg/dl; and/or
Glycosylated hemoglobin A1c equal or greater than 6.5; and/or
On oral hypoglycemic agents and/or insulin therapy;</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of impaired fasting glycemia and impaired glucose tolerance 6, 12 and 24 months after transplantation.</measure>
    <time_frame>6, 12 and 24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Following American Diabetes Association's definition:
Impaired fasting glycemia: fasting glucose levels between 100 and 125 mg/dl;
Impaired glucose tolerance: 2 hours' OGTT values between 140 and 199 mg/dl;</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Prevention of New Onset Diabetes Among Kidney Transplant Patients</condition>
  <arm_group>
    <arm_group_label>Insulin treatment for hyperglycemia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Table 1. NPH Insulin Titration Regimen for Patients in Group A Pre-dinner Capillary blood glucose	NPH dose initiation (IU/day)	NPH dose adjustment(IU/day) &gt; 240 mg/dl	                  14	                   Increase by 4 &gt; 180 mg/dl	                  12	                   Increase by 4 &gt; 140 mg/dl	                  10	                   Increase by 4 &gt; 120 mg/dl	                   0	                   Increase by 2 100 to 119 mg/dl	             0	                   Maintain the dose 80 - &lt;100 mg/dl	             0	                   Decrease by 4 60 - &lt;80 mg/dl	             0	                   Decrease by 8 &lt; 60 mg/dl	                    0	                  Give Â½ of previous dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients assigned in this arm will receive standard of care following their kidney transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin treatment for hyperglycemia</intervention_name>
    <arm_group_label>Insulin treatment for hyperglycemia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult patients (&gt; 18 years) with ESRD undergoing kidney transplantation;

          2. Standard triple immunosuppressive medications following kidney transplantation
             including tacrolimus, mycophenolate moftile and corticosteroids;

          3. Capable to understand the study protocol and to give informed consent;

        Exclusion Criteria:

        1. Type 1 and 2 DM either as co-morbidity or cause of ESRD;
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Akinlolu Ojo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane M Cibrik, MD</last_name>
      <phone>734-763-9031</phone>
      <email>dcibrik@med.umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer L Mawby, RN</last_name>
      <phone>734 936 4811</phone>
      <email>jlmawby@med.umich.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Diane M Cibrik, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Akinlolu Ojo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fu L Luan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 10, 2014</lastchanged_date>
  <firstreceived_date>August 30, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Fu L Luan</investigator_full_name>
    <investigator_title>Clinical Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Kidney transplant</keyword>
  <keyword>New onset diabetes</keyword>
  <keyword>Prevention</keyword>
  <keyword>Insulin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
